



OPEN

Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (*Phyllomedusa bicolor*): retrospective reports

Timo Torsten Schmidt^{1,2}, Simon Reiche², Caroline L. C. Hage², Felix BERPPOHL³ & Tomislav Majić^{2,3}✉

Kambô, the secretion of the Amazonian Giant Leaf Frog (*Phyllomedusa bicolor*) contains a plethora of bioactive peptides and was originally used by indigenous communities from the Amazon basin as medicine for improving hunting capacities. In the last 20 years, Kambô has spread to Western urban healing circles. To date it is still controversial whether the acute effects of Kambô include alterations of consciousness similar to known psychoactive substances like serotonergic psychedelics. Here we retrospectively assessed psychological effects of Kambô in a sample of anonymous users ($n = 22$, mean age: 39 years, ± 8.5 ; 45.5% female), administering standardized questionnaires for the assessment of altered states of consciousness (ASC), including the Altered States of Consciousness Rating Scale, the Phenomenology of Consciousness Inventory (PCI), the Mystical Experience Questionnaire (MEQ), the Challenging Experience Questionnaire (CEQ) for acute effects and the Persisting Effects Questionnaire (PEQ) and a scale assessing connectedness for subacute effects. The intensity of retrospectively reported acute psychological effects remained on a mild to moderate level, with no psychedelic-type distortions of perception or thinking. Conversely, persisting effects were predominantly described as positive and pleasant, revealing high scores on measures of personal and spiritual significance.

Kambô is the Matsé name for the secretion of the Giant Leaf Frog (*Phyllomedusa bicolor*), which is ritually used by different ethnicities in the Amazon basin of Brazil and Peru¹. A variety of potent bioactive peptides have been identified in the frog's secretion, including phyllocaerulein, phyllokinin, phyllomedusin, sauvagine, ceruletide², adenoregulin, and the potent opioids dermorphin and deltorphin¹. Kambô is obtained from the frog by carefully tying it up and rubbing its skin with a hard instrument, collecting the secretion on a wooden stick². It has been emphasized that in most cases the frog is treated with utmost respect and caution, in order to not harm it, and released it to its natural habitat once that the secretion is collected³.

Kambô is most commonly applied by the applicator to the recipient via several fresh superficial burns ("dots") on the arms, legs or chest⁴. It has been described that within minutes, the secretion likely enters the lymphatic system and subsequently the blood⁵, thereby inducing an intense reaction that includes hypotension, sweating, tachycardia, heavy vomiting and edema, usually subsiding within an hour⁶. This is followed by listlessness or sleep and, subsequently, a state "perhaps to be described as euphoric"¹, characterized by increased stamina and clarity of thoughts with an increased capacity for hunting¹. In Amazonian indigenous communities, Kambô is used as a cleansing ritual to enhance the recipient's hunting capacities once that cleansing has occurred and acute effects have subsided⁷. The recipient is thereby supposed to be liberated from "panema", originally meaning "bad luck in hunting" or "bad principles". Labate and Lima have pointed out, however, that the definition of "panema" has been broadened by urban Kambô practitioners, suggesting the notion of "Indian depression"⁷, accordingly making Kambô to a panacea to heal depression-like states and many other negative conditions and diseases.

¹Department of Education and Psychology, Neurocomputation and Neuroimaging Unit (NNU), Freie Universität Berlin, Berlin, Germany. ²Research Group Psychotropic Substances, Psychiatric University Clinic at Hospital St. Hedwig, Charité Universitätsmedizin Berlin, Berlin, Germany. ³Berlin Institute of Health, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Charité Mitte, Berlin, Germany. ✉email: tomislav.majic@charite.de

During the last 20 years, Kambô has found its way to Western urban centers in Brazil and all over the world⁸. From its Amazonian origins to its use in the context of Brazilian syncretic religions like the Santo Daime and the União do Vegetal⁷ and, finally, to its use in Western healing circles, Kambô has often been associated with the spread of the serotonergic psychedelic ayahuasca⁶. Ayahuasca is an Amazonian shamanic concoction of different plants, including plants (e.g. *Psychotria viridis*) which contain the serotonergic psychedelic N,N-dimethyltryptamine (N,N-DMT) and *Banisteriopsis caapi*, which contain inhibitors of monoaminoxidase (MAO-I) that render N,N-DMT orally active⁹. Notably, Kambô does not necessarily have to be applied by a shaman and is not considered as a shamanic ritual itself, in contrast to ayahuasca and other ritual plants, where use is restricted to a shamanic framework¹⁰. During its spread to Western urban centers, however, the Kambô ritual has been transformed from a hunting ritual into therapeutic approaches and a neo-shamanic healing ritual, a process which has been labeled as “shamanization of Kambô”¹¹.

In contrast to nature-derived serotonergic psychedelics, no serotonergic activity has been identified for Kambô up to date. However, the association with ayahuasca, is not the only connection to serotonergic psychedelics. Notably, different names used for the frog’s secretion include “Kambô”, “kampu”, “vaccino da floresta” and also “sapo”, which incorrectly means “toad” in Spanish. This variability of the terms has sometimes led to a confusion of Kambô with the secretion of the Sonoran Desert Toad (*Bufo alvarius*), which is also referred to as “sapo”⁶. In contrast to Kambô, however, the toad’s secretion contains the potent serotonergic psychedelics 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)¹² and bufotenine, which is usually smoked or snorted, immediately inducing strong psychedelic experiences¹³. Given the different application routes, the two substances are usually not confused by users, even though ceremonies where secretions from Kambô and *Bufo alvarius* are combined have recently been proposed in Western psychedelic circles.

Another interesting overlap between Kambô and the use of plant-derived psychedelics can be found in anecdotal reports describing beneficial after-effects on wellbeing, medical and mental health problems and personal and spiritual development¹⁴—attributes which have previously been associated with the use of serotonergic psychedelics. Of note, the effects of serotonergic psychedelics underlie unique temporal dynamics, with distinct acute (“psychedelic experiences” or “states”) and subacute effects (“afterglow” phenomena)¹⁵. Afterglow phenomena have been conceptualized as states of “elevated and energetic mood with a relative freedom from concerns of the past and from guilt and anxiety”, which are associated with an enhanced willingness “to enter into close interpersonal relationships”, lasting between 2 weeks and a month¹⁶. If these effects are comparable to the after-effects of Kambô is an open question.

Despite the close cultural and sub-cultural associations between the use of Kambô and different nature-derived psychedelics, no systematic characterization of the acute or subacute effects of Kambô has been reported. Here, we report results of a paper–pencil study among Kambô users employing standardized and validated questionnaires to retrospectively report acute and subacute effects of Kambô. As Kambô is typically applied with a healing purpose, the collected reports will be influenced by user’s expectations on positive effects, which might also be present in the given retrospective reports. The standardized assessment was intended to assess the pattern of effects (i.e. the relative strength of various consciousness aspects) and thereby allow a comparison to data from other psychoactive substances to answer in how far the effects of Kambô display similarities with serotonergic psychedelics¹⁷.

Our study was designed to (1) systematically characterize the retrospective report of acute effects of Kambô, enabling a comparison to acute effects of e.g. plant-derived serotonergic psychedelics, (2) explore if Kambô displays subacute effects which might be comparable to the psychedelic afterglow phenomena, including retrospective appraisal of the experiences by the recipients.

Results

Sample characteristics. We received $n = 27$ sets of anonymously completed paper–pencil questionnaires via mail, $n = 5$ of which were excluded due to an insufficient reliability index in the Phenomenology of Consciousness Inventory (PCI; cut-off $h > 2$), leaving a final dataset of $n = 22$ for the first part of the study. The consecutive part of the study on the subacute effects of Kambô was completed by $n = 14$, where one participants’ Persisting Effects Questionnaire (PEQ) data and one participants’ CS data were excluded due to inappropriate completion, leaving for each $n = 13$ datasets.

The sample characteristics are summarized in Table 1. With regards to lifetime drug consumption, 15 participants (68.2%) reported experiences with serotonergic hallucinogens—e.g., lysergic acid diethylamide (LSD), N,N-DMT, 2,5-Dimethoxy-4-methylamphetamine (DOM)—and 19 (86.4%) reported experiences with ritual plants or traditional indigenous medicines (e.g., ayahuasca, peyote, San Pedro, psilocybin mushrooms, ibogaine, 5-MeO-DMT, bufotenin). Participants reported consumption of other psychotropic substances in their lifetime as follows: cannabis ($n = 21$, 95.5%), opioids ($n = 7$, 32.8%), cocaine ($n = 10$, 45.5%), amphetamine ($n = 13$, 59.1%), 3,4-Methylenedioxy-N-methylamphetamine (MDMA) ($n = 15$, 68.2%), tranquilizer ($n = 4$, 18.2%).

Participants were asked to report on the importance of spiritual practices in their life on a scale from (0 = “not at all” to 100 = “extraordinarily important”), which resulted in an average of 72.7% ($\pm 21.8\%$).

Retrospective reports of acute subjective effects of Kambô. The Kambô secretion was administered for $n = 15$ (68.2%) participants by an alternative health practitioner, western healer or “neo-shaman”. In $n = 2$ (9.1%) cases an indigenous shaman and in $n = 3$ (13.6%) cases a layperson was reported to have administered Kambô ($n = 1$ “other” and $n = 1$ not specified). $N = 14$ (63.6%) of the participants reported being the only client while receiving Kambô, while $n = 7$ (31.8%) received it in a group setting ($n = 1$ not specified). The setting and environment was described as follows: a healing place or temple ($n = 11$, 52.4%), at home ($n = 4$, 19.0%), in

	Mean \pm SD	n (%)
Age	39.0 \pm 8.5	
Sex, female		10 (45.5)
Age, first Kambô experience	37.2 \pm 8.3	
Lifetime Kambô experiences	4.7 \pm 5.1	
Time since last Kambô experience		
< 1 week		11 (50.0)
1 week–30 days		4 (18.2)
31 days–12 months		1 (4.5)
1–5 years		3 (13.6)
> 5 years		2 (9.1)
No answer		1 (4.5)

Table 1. Sample characteristics of the n = 22 participants included in the analysis.

nature (n = 2, 9.5%), in a ceremony (n = 2, 9.5%), other (n = 2, 9.5%), in a friend's home (n = 1, 4.8%), with an alternative health practitioner practice (n = 1, 4.8%), at a festival (n = 1, 4.8%), on vacation (n = 1, 4.8%).

Participants reported that Kambô was applied via an average of 7 ± 2 burning points on the participants' skin. The acute experience lasted less than 15 min for n = 6 (27.3%) participants, between 30 and 59 min for n = 11 (50.0%) participants, 60 min or longer for n = 3 (13.6%) participants (n = 2 not specified). We asked participants explicitly if they thought that Kambô induces a "Rauschzustand" (German word for "inebriation" or "high"), and n = 5 (22.7%) reported "Yes".

Acute effects were assessed retrospectively using the ASC rating scale, the PCI, the mystical experiences questionnaire (MEQ) and challenging experience questionnaire (CEQ) to assess altered state experiences allowing for direct comparison to hallucinogenic substances and non-pharmacological methods that elucidate psychotropic effects. Figure 1 and Table 2 summarize results of the ASC rating scale, the PCI, MEQ30 and CEQ.

Subacute subjective effects of Kambô. The PEQ and the CS were filled in only when the exemplary Kambô session happened 2–3 weeks before filling in the questionnaires. Together these questionnaires cover a broad spectrum of subjectively experienced subacute effects. Results are summarized in Fig. 2 and Table 3.

When asked about the spiritual relevance of the Kambô experiences, n = 6 of 13 (46%) participants rated it as strongly spiritually significant, including n = 2 participants who rated it as the single most or among the five most spiritually significant experiences of their life. When asked how personally meaningful the experience was, n = 7 of 13 (54%) participants rated the experience among the ten most meaningful experiences of their life and n = 4 rated it among the five most personally meaningful experience. One participant viewed it as the single most personally meaningful experience in his life. Regarding change of well-being or life satisfaction, n = 8 of 13 (62%) participants stated that the experience increased well-being or life satisfaction slightly, and n = 5 of 13 (38%) participants reported an increase in well-being or life satisfaction between 'moderate' and 'very much'.

Discussion

In our study investigating subjective retrospective reports of effects of Kambô—the secretion of the Giant Maki Frog (*Phyllomedusa bicolor*)—on human consciousness, we report three major findings: (1) regarding the acute period of the pharmacological action, only subtle effects on consciousness were reported, not comparable to serotonergic psychedelics with regard to qualitative aspects and intensity; (2) participants reported positive subacute after-effects, which in some aspects showed overlaps with psychedelic "afterglow" phenomena; (3) about half of the participants retrospectively appraised their experiences with Kambô as both highly spiritually and personally relevant for their lives, analogous to appraisals of mystical experiences reported under high dosages of serotonergic psychedelics. The interpretation of our exploratory study is limited by the lack of the possibility to include a control/placebo condition as it would be applied in a controlled open-label trial. Despite a potential bias towards supposedly positive Kambô effects, the pattern of responses on the applied questionnaires (differences between the factors), renders the reported effects different from other psychoactive substances like serotonergic psychedelics. This is especially the case, as most participants have had previous experiences with psychedelics.

Assessment of the dosage of Kambô was reported to be 7 ± 2 burning dots. As no quantification of the composition of the Kambô preparation and no standardized amount per dot was possible to assess, our data does not allow to make statements of dose–response relationships, even if these have been anecdotally suggested in the literature¹⁸. Instead, it provides a first exploratory analysis on the general pattern of effects that participants experience upon Kambô administration.

Reports of acute effects of Kambô. In the first part of our study, we set out to test if users report the Kambô induced acute effects as altered states of consciousness (ASCs) comparable to psychedelics. The core of psychedelic experience is currently best assessed with the ASC rating scale, the most commonly used tool to assess drug-induced ASCs. It allows for characterization of subjective effects along 11 factors of change in conscious experience. Psychedelic experiences are typically characterized by high scores on the scales *Elementary*




Figure 1. Retrospectively reported acute subjective effects of Kambô. Acute effects ($n = 22$) were assessed with standardized psychometric tools that allow comparisons to consciousness alterations induced by different methods as e.g. found on the Altered States Database¹⁷. The scores of the ASC, MEQ and CEQ are designed to assess differences from zero, while the PCI items are anchored with two opposing statements (See “Methods”) to the end of the scale [0: minimum; 6: maximum], thereby not assessing differences from zero but characterizing the overall pattern of experience. In comparison to Table 2, the box plots provided here show the data distribution.

and *Complex Imagery*, *Insightfulness*, *Spiritual Experience*, *Experience of Unity* and *Blissful State*¹⁷. In contrast, for Kambô we found only relatively low scores on these dimensions. Thus, our study demonstrates with standardized questionnaire data that the acute effects of Kambô are not reported to include effects on consciousness comparable to serotonergic psychedelics, especially no comparable effects are reported on perception and thinking.

Moreover, we applied the Mystical Experience Questionnaire (MEQ). This tool is used to test for the occurrence of spiritual/mystical experiences, which are thought to have the potential to facilitate conversions, attitude-changes, or even life-changes under special circumstances. High values of “full-blown” mystical experiences have been reported for several serotonergic psychedelics including LSD¹⁹, psilocybin²⁰, and 5-MeO-DMT²¹. In our sample, few participants reported to have had experienced pronounced aspects of mystical experiences, reflected by relatively low mean scores on the four MEQ factors, with a few higher outlier datapoints. Even if Kambô effects cannot be compared to intense mystical experiences as reported after the use of serotonergic psychedelics²² with regard to intensity and completeness of the mystical state, our finding suggests that participants might have experienced psychological and spiritual effects beyond merely somatic reactions. However, this conclusion remains somewhat speculative, as expectational and setting factors could have contributed to these reports. In order to explain Kambô’s potential therapeutic mechanisms of action, Hesselink and Winkelman¹⁰ proposed a conceptual model in which different aspects interact: (1) potent pharmacological effects of the various bioactive peptides, including effects on the autonomous and somatic nervous system (2) psychological effects of ritual frameworks and expectations associated with Kambô, and (3) symbolic and metaphorical aspects, associated with the experience of a strong physical, psychological and spiritual cleansing process induced by Kambô. This is in line with observations suggesting that the interplay between pharmacological effects and a spiritual perspective might underlie potential healing processes in Kambô⁷.

Given the complex interactions between pharmacological and non-pharmacological mechanisms, however, it remains speculative how specific peptides would relate to the reported psychological effects. Placebo-controlled studies investigating the individual components of Kambô would be needed to identify their contributions. Especially for the observed subacute effects it remains an interesting question for future research, if these are mediated by a direct pharmacological action or what more complex physiological mechanisms contribute to them.

The Challenging Experience Questionnaire (CEQ) includes self-report items designed for the investigation of challenging experiences under psilocybin and other serotonergic psychedelics. These include fear, grief, physical distress, insanity, isolation, fear of death and paranoia, which are symptoms that can occur in challenging experiences (also referred to as “bad trips”) under serotonergic psychedelics²³. The challenging experiences reported

	Mean	SD	T	p
5D-ASC				
Total ASC score	13.0	12.4	4.94	0.000
Oceanic Boundlessness	19.1	21.2	4.22	0.000
Dread of Ego Dissolution	10.5	11.5	4.26	0.000
Visionary Reconstructualization	7.0	10.0	3.26	0.002
Auditory Alterations	3.4	6.3	2.57	0.009
Vigilance Reduction	20.5	17.3	2.84	0.005
11-ASC				
Experience of Unity	18.7	26.8	3.27	0.002
Spiritual Experience	24.8	26.3	4.42	0.000
Blissful State	23.5	28.0	3.94	0.000
Insightfulness	12.0	19.2	2.93	0.004
Disembodiment	9.7	15.7	2.89	0.004
Impaired Control and Cognition	9.1	13.6	3.15	0.002
Anxiety	7.1	9.6	3.47	0.001
Complex Imagery	9.4	16.4	2.68	0.007
Elementary Imagery	8.1	15.5	2.46	0.011
Audio-Visual Synesthesia	11.6	13.1	4.15	0.000
Changed Meaning of Percepts	8.3	13.9	2.82	0.005
PCI				
Altered State of Awareness	2.4	1.9		
Altered Experience	1.9	1.4		
Volitional Control	2.9	1.1		
Self-Awareness	4.7	1.1		
Rationality	4.3	1.1		
Internal Dialogue	0.7	1.4		
Positive Affect	1.4	1.1		
Negative Affect	1.1	1.1		
Imagery	1.6	1.2		
Attention	4.5	0.9		
Memory	4.4	1.3		
Arousal	2.7	1.9		
Body Image	1.8	1.5		
Time Sense	2.2	1.8		
Perception	1.0	1.1		
Meaning	2.3	1.7		
Joy	1.5	1.7		
Sexual excitement	2.5	1.8		
Love	0.6	1.4		
Anger	0.6	1.4		
Sadness	0.8	1.2		
Fear	1.9	1.9		
Imagery amount	1.0	1.3		
Imagery vividness	2.3	1.7		
Direction of attention	4.3	1.2		
Absorption	4.8	1.0		
MEQ				
Mystical	25.7	25.1	4.79	0.000
Positive Mood	33.5	26.4	5.95	0.000
Transcendence of time and space	20.2	21.8	4.34	0.000
Ineffability	46.1	27.0	8.01	0.000
Total Score	28.5	23.4	5.72	0.000
CEQ				
Fear	18.2	21.9	3.53	0.001
Grief	23.5	27.1	3.68	0.001
Physical Distress	34.0	17.9	8.07	0.000
Continued				

	Mean	SD	T	p
Insanity	7.6	14.6	2.20	0.021
Isolation	9.4	17.3	2.30	0.017
Death	8.6	21.0	1.74	0.050
Paranoia	0.5	2.1	0.90	0.189

Table 2. Group level summary statistics for acute effects. $N = 22$; To allow comparison with previous datasets mean \pm SD for all group level scores of the applied questionnaires are provided. For the 5D-ASC, the ASC in its 11 factor analysis, MEQ, CEQ scores, we performed one sample t-tests ($df = 21$) against zero and provide p-values. Please note that data is reported in its completeness and raw significance values are reported instead of significance thresholding. The scores of the ASC, MEQ and CEQ are designed to assess differences from zero, while the PCI items are anchored with two opposing statements (See “Methods”) to the end of the scale [0: minimum; 6: maximum], therefore not being tested against zero.




Figure 2. Subacute subjective effects of Kambô. Subacute effects ($n = 13$) were assessed with the PEQ and the CS and are displayed as box plots for the dimensions or items of the two questionnaires. In comparison to Table 3, the box plots provided here illustrate the data distribution.

for acute effects of Kambô were mostly limited to “physical distress”. Challenging experiences of a rather psychological nature were barely reported—suggesting unspecific fearful reactions to the strong vegetative effects, but without induction of psychedelic-type psychological crises including insanity, isolation, death or paranoid ideation in the sense of “bad trips”, reflecting distortions of ego functions and self-processing. In addition to the risk of fearful physical reactions, a few case reports have been published highlighting severe complications that might have been associated with Kambô use, including psychological problems like a case of psychosis²⁴, and physical side effects like dermatomyositis²⁵, toxic hepatitis²⁶ and a case of sudden death²⁷ possibly related to Kambô. In addition, several cases of hyponatraemia^{28,29} and syndrom of inappropriate antidiuretic hormone secretion (SIADH)³⁰ have been reported, probably associated with excessive water intake during some Kambô ceremonies.

Ratings on the PCI allow for comparison of Kambô experiences with hypnosis or meditation techniques to investigate potential shared aspects. Similar to hypnotic or meditative states, participants reported to have had experienced a reduction of positive and negative affect³¹. With regard to the question if or how Kambô elicits psychoactive effects, it is noteworthy that the obtained scores on “self-awareness”, “rationality”, “attention” and “memory” indicate that the participants did not feel confused or muddled—at least according to their retrospective memory of the state—which would be expected from centrally active drugs like alcohol or barbiturates.

Taken together, our study provides standardized data that allows a comparison of reported Kambô experiences to the effects of well-known psychoactive substances. On the physiological level, the acute Kambô experience was reported to be dominated by an intensive physical reaction, which is reflected in the reports of “physical distress” by our participants and is also likely to have triggered psychological distress in some participants. The

	Mean	SD	T	p
Persistent Effects Questionnaire (PEQ)				
Positive attitudes about life or self	56.6	18.7	10.89	0.000
Negative attitudes about life or self	3.7	6.6	2.02	0.033
Positive mood changes	58.1	25.9	8.10	0.000
Negative mood changes	0.8	2.8	1.00	0.169
Altruistic/positive social effects	47.5	23.2	7.38	0.000
Antisocial/negative social effects	6.2	9.1	2.44	0.016
Positive behaviour changes	64.6	27.3	8.54	0.000
Negative behaviour changes	6.2	17.1	1.30	0.109
Connectedness Scale (CS)				
I have felt that everything is interconnected	36.8	30.8		
I have seen things from a broad perspective; the 'bigger picture'	41.9	33.6		
I have felt connected to a source of universal love	40.7	36.2		
I have felt connected to a spiritual essence (in the secular or religious sense)	42.8	29.8		
I have felt connected to nature	63.2	36.6		
I have felt connected to a purpose in life	44.2	31.2		
I have felt separate from the world around me	16.2	16.8		
I have felt unwelcome amongst others	13.2	14.4		
I have felt connected to all humanity	33.9	32.1		
I have felt connected to strangers	29.7	28.3		
I have felt connected to a community	35.2	33.4		
I have felt connected to friends and/or family	36.5	31.9		
I have felt alone	19.2	19.2		
I have been able to fully experience emotion, whether positive or negative	70.8	25.6		
I have felt connected to my values	50.4	36.8		
I have felt connected to insight/intuition	63.2	32.6		
I have felt connected to deeper aspects of myself	51.6	36.4		
I have felt connected to my body	60.8	28.4		
If I had chosen to, I could have 'sat with' painful memories	28.6	30.7		
I have felt connected to a range of emotions	51.3	29.4		
I have felt connected to my senses (touch/taste/sight/smell/hearing)	54.6	26.3		
My mind has felt connected to my heart/emotions	45.8	30.1		
I have felt trapped in my mind	5.0	3.0		

Table 3. Group level summary statistics for subacute effects. Note that data (n = 13, each for CS and PEQ) is reported in its completeness and raw significance values are reported instead of significance thresholding. For the PEQ scores we performed t-tests against zero and provide p-values.

assessment in the present study indicates that Kambô induces a state of self-centered inwardness. The pattern of responses does not match with typical characteristics of psychedelic-induced states. Although the pharmacodynamics of the Kambô secretion have only been partially investigated, it has been suggested that Kambô's pharmacological effects are restricted to the cardiovascular, gastroenterological, endocrine and immune systems, the autonomic nervous system and the endogenous opioid system¹⁰. On the one hand, this appears to be plausible given the compounds' peptide structures which prevent them from passing the blood-brain barrier. On the other hand, the authors hypothesize that the neuropeptide opioids in Kambô (dermorphin and deltorphin) could be responsible for the observed "alterations of consciousness", suggesting psychoactive effects. However, given the neuropeptide structure, these opioids have been reported to be centrally active via intrathecal application only. In addition, the reported acute and subacute effects of Kambô resemble stimulant effects rather than those of substances with mu-receptor activity. Thus, the given reports of acute and subacute effects in our sample are divergent from known psychoactive effects of mu-receptor agonists, suggesting that other compounds or complex interactions between vegetative, neuro-endocrinological and psychological effects might be considered as underlying biological correlates of the Kambô experience. Nevertheless, to date no compounds have been identified that could explain the induction of an ASC during the acute period of Kambô effects and no such phenomena were reported by our participants.

The subacute effects of Kambô. In the second part of our study, we retrospectively investigated subacute effects of Kambô up to 2–3 weeks after the reported exemplary session to find first indications if these effects were comparable to psychedelic afterglow phenomena (See¹⁵). Since no systematic characterization of afterglow phenomena exists to date, even for psychedelics, a quantitative comparison was not possible. Therefore, as a

first description of the subacute effects we used the PEQ, previously applied to characterize psychedelic effects mainly in therapeutic contexts. Additionally, we used a questionnaire measuring connectedness, which has not yet been validated.

Notably, subacute effects of Kambô were appraised very positively, including factors of “positive attitudes”, “positive mood”, “altruistic” and “positive behavioral changes”, whereas negative aspects have been reported to be negligible. This is in line with observations describing a euphoric state after the acute effects of Kambô have subsided¹. Moreover, subacute effects involved dimensions of mood, overall wellbeing, but also aspects on a spiritual and transpersonal level. The intensity of subacute positive effects was pronounced, even if not as intense as after-effects of LSD³² or psilocybin³³.

Interestingly, the ratings of items describing connectedness to *internal* aspects of oneself were high in our sample, such as being connected to “my senses”, “a range of emotions”, “my body”, “deeper aspects of myself” and “insight/intuition”, and to “have been fully able to experience emotion, whether positive or negative”. In contrast, ratings of items referring to connectedness to *external* aspects (e.g. “a community”, “strangers”, “all humanity”, “a purpose in life”, “spiritual essence” and “a source of universal love”) were far less pronounced, except for the experience of being “connected to nature”. This is in line with anecdotal observations including participants’ subjective experiences of an active interaction with a frog’s “spirit”, which detects and eliminates toxins and bad energy from their mind and body¹⁰. However, this finding is only partially comparable to mystical experiences associated with acute and subacute effects of serotonergic psychedelics, where states of increased connectedness to both the self and other beings have been reported³³ (i.e. the notion that “everything is interconnected”).

Notably, even if the subacute effects were not comparable to those reported after the use of serotonergic psychedelics regarding intensity and qualitative aspects^{32,33}, some of the phenomena which outlasted the acute effects were surprisingly intensive and complex, showing overlaps with psychedelic “afterglow phenomena”, including increases in positive mood, behavior, attitudes and social interaction.

Limitations

The effects of Kambô reported by our study participants could partially be related to the ritualistic setting of consumption. Our data were collected retrospectively from a group of Western Kambô users recruited through a public workshop on Kambô and a group of practitioners devoted to a specific ritual setting. This might have induced a bias of expectations or motivations for use and thereby involved the placebo dimension. The observed variability in the assessed acute effects suggests that expectational factors and setting might have played a role for some reports. In order to make final conclusions about the psychoactive properties of Kambô, randomized placebo-controlled trials are necessary.

Conclusion

Our data shows that the retrospective reports of acute Kambô effects are very different from the effects of serotonergic psychedelics. While the acute effects of Kambô were reported to be dominated by strong physical reactions followed by a state of increased inwardness, psychedelic effects appear to facilitate loosening of ego barriers and increased connectedness with oneself and the outer world. Our findings are congruent with anecdotal reports that the subacute effects of Kambô include feelings of being energized with increased stamina and clarity of thoughts, following an initial state of physical sickness and exhaustion. Nevertheless, subacutely, Kambô does exhibit some overlap with serotonergic psychedelics in regard to the reported “afterglow” phenomenon¹⁶. This finding is remarkable given the unique temporal dynamics of subacute psychedelic effects, incomparable to any other group of psychoactive substances. Kambô thereby appears to be associated with afterglow-like effects, but without preceding psychedelic states. In agreement with our findings, it has been suggested that the transformative and transpersonal effects of Kambô might be comparable to those associated with the use of serotonergic psychedelics¹⁰.

Methods

Participants and procedure. All data of this study was collected anonymously. Potential participants were recruited at a drug information event in Berlin and through Kambô practitioners who forwarded study material to their clients. Participants were informed about the study aim and that data collection is fully anonymously. They were handed out a printed set of paper/pencil-questionnaires together with a pre-paid envelope for returning completed sets of questionnaires and gave consent by filling the questionnaire and sending it back anonymously. All procedures were conducted in accordance with the Declaration of Helsinki and were approved by the Ethics committee of the Charité Universitätsmedizin Berlin (EA2/185/17). All questionnaires were applied in German. The first set of questions addressed person specific characteristics, such as age, gender and drug consumption history.

Apart from questions referring to demographic information, a set of questionnaires was given to the participants that comprised the following two parts: (1) questionnaires on the acute effects of an exemplary Kambô session, (2) questionnaires on subacute effects of the exemplary Kambô session. All participants were requested to fill in demographic information and (1). Participants were asked to fill in (2) only if the exemplary Kambô session that they reported about in (1) happened between 2 and 3 weeks ago, as the questions on the acute effects addressed this period after the Kambô session.

As exclusion criterion for data of insufficient quality we used the reliability index (h) of the PCI, which is a measure for the participants consistency in completing the questionnaire³⁴.

Assessment of acute subjective effects of Kambô. The second set of questions comprised four well established and validated psychometric tools to assess acute subjective experiences of consciousness alterations:

Altered States of Consciousness (ASC) Rating Scale: The ASC rating scale^{35,36} originated from two former versions, the initial APZ (Abnormal Mental States; GERMAN: Abnorme Psychische Zustände)^{37–39} and the revised version OAV⁴⁰ and has become one of the most frequently used questionnaires in the assessment of altered states of consciousness phenomena. The ASC rating scale is supposed to investigate characteristics of consciousness alterations that are invariant across various conditions including both pharmacological (e.g., psilocybin, ketamine, DMT) and behavioral induction methods (e.g., sensory deprivation, hypnosis, autogenic training). Over the course of more than 30 years, the questionnaire underwent several refinements finally leading to the currently used version which comprises 94 items^{35,36}. Currently two different analysis schemata are used: the original 5-dimensional scheme (5D-ASC) and the 11-factorial scheme (11-ASC)⁴¹.

Phenomenology of Consciousness Inventory (PCI): The PCI was developed in the context of an interdisciplinary approach described as empirical-phenomenology^{31,34}. Most notably influenced by Tart's⁴² conception of ASCs, where different states are characterized by distinct structures and patterns of the subjective experience. The PCI assesses subjective experiences along multiple dimensions, where corresponding scales were constructed on the basis of several cluster and factor analyses. Items are presented as two opposing statements (e.g. "I felt ecstatic and joyful"—"I felt no feelings of being ecstatic and joyful") located on the two poles of a 7-point Likert scale. We used the German version by Rux (2002)⁴³.

Mystical Experiences Questionnaire (MEQ): The MEQ was first used in the 'Good Friday Experiment'^{44,45}, where it was intended to assess differences regarding aspects of mystical experience between a group taking psilocybin and a control group taking a placebo. Since then, the MEQ has been applied as an instrument for the quantitative assessment of pharmacologically induced mystical experience. Items of the MEQ were chosen based on literature about mysticism including first-person accounts as well as theoretical work, most notably by W. James (1902) and W. T. Stace (1960). The initial MEQ has been further developed by Pahnke (1969), Richards (1975), Griffiths et al. (2006, 2011), and MacLean et al. (2012). The most recent version is the MEQ30⁴⁶, a condensed version of the MEQ with thirty items and four empirical scales^{47,48}.

Challenging Experiences Questionnaire (CEQ): The CEQ was designed to provide a tool for the comprehensive assessment of acute negative effects of temporarily induced altered states of consciousness⁴⁹, based on three questionnaires: Hallucinogenic Rating Scale (HRS), 5D-ASC, and States of Consciousness Questionnaire (SOCQ). The conceptual scope of the 26-item CEQ is informed by literature on psychological and physical distress following hallucinogen intake and covers a variety of adverse cognitive, affective, and somatic reactions which are clustered into seven distinct dimensions of challenging experiences⁴⁷. Analyzing data from an online survey on negative experiences with psilocybin, corresponding scales for the first six dimension were derived by exploratory factor analysis, complemented by the Paranoia scale, and subsequently validated through confirmatory factor analysis⁴⁹. Items are rated on a 6-point scale adopted from the SOCQ.

Assessment of subacute subjective effects of Kambô. The third set of questionnaires addressing subacute effects was introduced with the instructions to fill out the following questionnaires only if the exemplary Kambô session (for which the acute effects were reported) had happened up to 3 weeks before the day of completing the questionnaire. The set of questions comprised the following two questionnaires:

Items about Connectedness: We used a previously unpublished set of 23 questions to measure different aspects of connectedness⁵⁰. The items include aspects of connectedness to one's self, connectedness to the universe and connectedness to others. The items stem from the development of a *connectedness scale* (CS). As no validation or confirmation of a factor structure had been published until now, the scores on this scale are presented for the individual items.

Persisting Effects Questionnaire (PEQ): The PEQ was developed as a follow-up questionnaire to the States of Consciousness Questionnaire (SOCQ), which was an intermediate version of the MEQ²². The PEQ assesses long-term changes in participants. We used a German version of the extended PEQ version reported in³³. This version uses 140 items rated on a 6-point Likert scale from 0 ('not at all') to 5 ('extremely'), and three items on the retrospective assessment of the importance and effects of the experiences.

Data analysis and visualization. Questionnaire data were analyzed using standardized analysis sheets. Data visualization was performed with RStudio v.1.2.1335 and package ggplot2 v.3.2.1. Boxplots represent the lower and upper hinges corresponding to the first and third quartiles (the 25th and 75th percentiles), the median as a horizontal bar and the whiskers indicate the range of the data (limited to 1.5× interquartile range). Discrete individual data points are shown as green dots. To display overlapping data points the size of the dots represents the number of observations at each value. Data points not lying within the range of the whiskers are outliers. The mean, without any outlier exclusion, is displayed as a diamond shape. For comparability with previous reports, the means and SD for all questionnaire data are provided in Table 2 (without outlier exclusion).

Data availability

Data is available upon personal request.

Received: 20 June 2020; Accepted: 20 November 2020

Published online: 09 December 2020

References

1. Daly, J. et al. Frog secretions and hunting magic in the upper Amazon—Identification of a peptide that interacts with an adenosine receptor. *Proc. Natl. Acad. Sci. USA* **89**(22), 10960–10963. <https://doi.org/10.1073/pnas.89.22.10960> (1992).

2. Erspamer, V. *et al.* Pharmacological studies of “sapo” from the frog *Phyllomedusa bicolor* skin: A drug used by the Peruvian Matses Indians in shamanic hunting practices. *Toxicol* **31**(9), 1099–1111. [https://doi.org/10.1016/0041-0101\(93\)90125-3](https://doi.org/10.1016/0041-0101(93)90125-3) (1993).
3. den Brave, P. S., Bruins, E. & Bronkhorst, M. W. G. A. *Phyllomedusa bicolor* skin secretion and the Kambó ritual. *J. Venom. Anim. Toxins. Incl. Trop. Dis.* <https://doi.org/10.1186/1678-9199-20-40> (2014).
4. Keppel Hesselink, J. M. Kambó: A ritualistic healing substance from an Amazonian frog and a source of new treatments. *Open J. Pain Med.* **2**(1), 4–6. <https://doi.org/10.17352/ojpm.000007> (2018).
5. Keppel Hesselink, J. M. & Schatman, M. E. Rediscovery of old drugs: The forgotten case of dermorphin for postoperative pain and palliation. *J. Pain Res.* **11**, 2991. <https://doi.org/10.2147/JPR.S186082> (2018).
6. Keppel Hesselink, J. M. Kambó: A shamanistic ritual arriving in the west—Description, risks and perception by the users. *Int. J. Psychol. Psychoanal.* **4**(2), 4. <https://doi.org/10.23937/2572-4037.1510034> (2018).
7. Labate, B. C. & de Lima, E. C. Medical drug or shamanic power plant: The uses of Kambó in Brazil. *Ponto Urbe.* **15**, 1–19. <https://doi.org/10.4000/pontourbe.2384> (2015).
8. de Lima, E.C., Labate, B.C. A expansão urbana do anuro kampo (Phyllomedusa bicolor): Notas etnográficas. *Drog. Perspect. em Ciências. Humanas.* 315–344, (2008).
9. McKenna, D. J., Towers, G. H. N. & Abbott, F. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β -carboline constituents of Ayahuasca. *J. Ethnopharmacol.* [https://doi.org/10.1016/0378-8741\(84\)90003-5](https://doi.org/10.1016/0378-8741(84)90003-5) (1984).
10. Keppel Hesselink, J. M. & Winkelman, M. Vaccination with Kambó against bad influences: Processes of symbolic healing and ecotherapy. *J. Transpers. Psychol.* **51**(1), 28–48 (2019).
11. de Lima, E. C. & Labate, B. C. “Remédio da Ciência” e “Remédio da Alma”: Os usos da secreção do kambó (*Phyllomedusa bicolor*) nas cidades. *CAMPOS Rev. Antropol. Soc.* <https://doi.org/10.5380/cam.v8i1.9553> (2014).
12. Erspamer, V., Vitali, T., Roseghini, M., Cei, J. 5-Methoxy- and 5-hydroxy-indolealkylamines in the skin of *Bufo alvarius*. *Experientia.* **21**(504), (1965).
13. Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M. & Renn, E. The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. *J. Psychopharmacol.* <https://doi.org/10.1177/0269881118769063> (2018).
14. Keppel Hesselink, J. M. Kambó: A shamanic medicine—Personal testimonies. *Juniper Online J. Case Stud.* **8**(3), 555739. <https://doi.org/10.19080/fojcs.2018.08.555739> (2018).
15. Majić, T., Schmidt, T. T. & Gallinat, J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. *J. Psychopharmacol.* **29**, 3. <https://doi.org/10.1177/0269881114568040> (2015).
16. Pahnke, W. N. The psychedelic mystical experience in the human encounter with death. *Harv. Theol. Rev.* **62**, 1–21. <https://doi.org/10.1017/S0017816000027577> (1969).
17. Schmidt, T.T., Berkemeyer, H. The Altered States Database: Psychometric data of altered states of consciousness. *Front. Psychol.* (2018).
18. Gorman, P. *Sapo in My Soul: The Matsés Frog Medicine*. 1st ed. (Gorman Bench Press, 2015).
19. Liechti, M. E., Dolder, P. C. & Schmid, Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. *Psychopharmacology* <https://doi.org/10.1007/s00213-016-4453-0> (2017).
20. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology* **187**(3), 268–283. <https://doi.org/10.1007/s00213-006-0457-5> (2006).
21. Barsuglia, J. *et al.* Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. *Front. Psychol.* <https://doi.org/10.3389/fpsyg.2018.02459> (2018).
22. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology* **187**, 268–283. <https://doi.org/10.1007/s00213-006-0457-5> (2006).
23. Carbonaro, T. M. *et al.* Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *J. Psychopharmacol.* <https://doi.org/10.1177/0269881116662634> (2016).
24. Roy, R., Baranwal, A. & Espiridion, E. Can overuse of Kambó cause psychosis?. *Cureus.* <https://doi.org/10.7759/cureus.2770> (2018).
25. de la Vega, M., Maldonado, G. & Kraus, A. Dermatomyositis induced by the secretion of *Phyllomedusa bicolor* or Kambó frog—A case report. *Toxicol* <https://doi.org/10.1016/j.toxicol.2020.05.018> (2020).
26. Joanna, P. & Lapiński, T. W. Toxic hepatitis caused by the excretions of the *Phyllomedusa bicolor* frog—A case report by the excretions of the *Phyllomedusa bicolor* frog—A case report. *Clin. Exp. Hepatol.* **3**(1), 33. <https://doi.org/10.5114/ceh.2017.65228> (2017).
27. Aquila, I. *et al.* The biological effects of Kambó: Is there a relationship between its administration and sudden death?. *J. Forensic Sci.* **63**(3), 965–968. <https://doi.org/10.1111/1556-4029.13641> (2018).
28. Agüero-González, D.L., Pané-Vila, A., Gil, V., Castro, P. Severe hyponatremia after a purification ritual using an amazonian frog poison (Kambó). *Emergencias.* (2019).
29. Campodónico, J. *et al.* Severe hyponatremia secondary to *Phyllomedusa bicolor* (Kambó frog) poisoning. Report of one case. *Rev. Med. Chil.* <https://doi.org/10.4067/S0034-98872019000700935> (2018).
30. Leban, V., Kozelj, G. & Brvar, M. The syndrome of inappropriate antidiuretic hormone secretion after giant leaf frog (*Phyllomedusa bicolor*) venom exposure. *Toxicol* **120**, 107–109. <https://doi.org/10.1016/j.toxicol.2016.07.007> (2016).
31. Pekala, R. *The Phenomenology of Consciousness Inventory*. Thorndale PA: Psychophenomenological Concepts (now published by Mid-Atlantic Educational Institute, See Pekala 2001). (1982).
32. Schmid, Y. & Liechti, M. E. Long-lasting subjective effects of LSD in normal subjects. *Psychopharmacology* <https://doi.org/10.1007/s00213-017-4733-3> (2018).
33. Griffiths, R. R. *et al.* Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. *Psychopharmacology* **218**, 649–665. <https://doi.org/10.1007/s00213-011-2358-5> (2011).
34. Pekala, R. *Quantifying Consciousness: An Empirical Approach* (Plenum Press, New York, 1991).
35. Dittrich, A., Lamparter, D., Maurer, M. 5D-ABZ: Fragebogen Zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine Kurze Einführung [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]. Zürich, Switzerland, 2006.
36. Dittrich, A., Lamparter, D. & Maurer, M. 5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction 3rd edn. (PSIN PLUS, Zürich, 2010).
37. Dittrich, A. Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände [Construction of a questionnaire (APZ) for assessing abnormal mental states]. *Z. Klin. Psychol. Psychiatr. Psychother.* **23**, 12–20 (1975).
38. Dittrich, A. *Ätiologie-Unabhängige Strukturen Veränderten Wachbewusstseinszustände* (Enke, Stuttgart, 1985).
39. Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. *Pharmacopsychiatry.* **31**(Suppl 2), 80–84. <https://doi.org/10.1055/s-2007-979351> (1998).
40. Bodmer I, Dittrich A, Lamparter D. Aussergewöhnliche Bewusstseinszustände - Ihre gemeinsame Struktur und Messung [Altered states of consciousness - Their common structure and assessment]. In: Hofmann A, Leuner H, eds. *Welten Des Bewusstseins. Bd. 3*. Berlin, Germany: Experimentelle Psychologie, Neurobiologie und Chemie.; 1994:45–58.
41. Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. *PLoS One.* 2012;7. doi:<https://doi.org/10.1371/journal.pone.0030800>

42. Tart, C.T. States of consciousness and state-specific sciences. *Science* 176(4040):1203–1210. <https://doi.org/10.1126/science.176.4040.1203> (1972).
43. Rux. Erprobung der deutschen Übersetzung des Phenomenology of Consciousness Inventory von Pekala: Normwerte, Gütekriterien, Änderungsvorschläge. 2002.
44. Pahnke, W. N. *Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness* (Harvard University Press, Cambridge, 1963).
45. Pahnke, W.N. Drugs and mysticism. *Int. J. Parapsychol.* 8, 295–314 (1966). <http://docs.google.com/a/religionandcognition.com/fileview?id=F9d41d6a0-0d13-4dc4-b719-04218b36d632>.
46. MacLean, K. A., Leoutsakos, J. M. S., Johnson, M. W. & Griffiths, R. R. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. *J. Sci. Study Relig.* 51, 721–737. <https://doi.org/10.1111/j.1468-5906.2012.01685.x> (2012).
47. Barrett, F. S. & Griffiths, R. R. The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al. (2016). *Hum. Psychopharmacol.* 32(1), 2564. <https://doi.org/10.1002/hup.2564> (2016).
48. Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. *J. Psychopharmacol.* <https://doi.org/10.1177/0269881115609019> (2015).
49. Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M.S., Johnson, M. W. & Griffiths, R. R. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. *J. Psychopharmacol.* 30(12), 1279–1295. <https://doi.org/10.1177/0269881116678781> (2016).
50. Watts, R., Day, C., Krzanowski, J., Nutt, D. & Carhart-Harris, R. Patients' accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. *J. Human. Psychol.* 57(5), 520–564 (2017).

Acknowledgements

The authors would like to thank Tobias Thon[†] for help in recruitment of participants and Amy Romanello for proof reading of the manuscript.

Author contributions

T.T.S. and T.M. designed the study. T.T.S., C.H. and S.R. analyzed the data, S.R. designed figures and tables and T.T.S., T.M. and F.B. wrote the manuscript. All authors edited the manuscript and approved its final version. All authors agreed to be personally accountable for their own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to T.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020